MDS Inc. normal course issuer bid
17 Juni 2004 - 3:00PM
PR Newswire (US)
MDS Inc. normal course issuer bid TORONTO, June 17
/PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS; NYSE: MDZ) announced
today it has filed a Notice of Intention to make a normal course
issuer bid to purchase up to 11,945,440 (10% of the public float of
119,454,399) Common Shares from time to time during the next 12
months, if deemed appropriate by the Chief Executive Officer and
Chief Financial Officer of the Company. This will replace the
Normal Course Issuer Bid, which expires on June 20, 2004, under
which purchases of 35,000 Common Shares at an Average Price of
$17.5988 were made. Under the new bid, MDS may purchase up to
11,945,440 Common Shares. As of May 31, 2004, there were
141,881,728 Common Shares issued and outstanding. The purchases may
begin June 21, 2004 and will end no later than June 20, 2005. The
shares will be purchased through the facilities of the TSX at
market price. Since all purchases of Common Shares associated with
the issuer bid will be made in the open market, the Company is not
in a position to know the identity of those from whom it may
purchase Common Shares. To the best of its knowledge and belief,
after reasonable enquiry, no director, senior officer, associate of
a director or senior officer of the Company, or person acting
jointly or in concert with the Corporation, intends to dispose of
shares under this normal course issuer bid. The Company has
determined that any purchase of its outstanding Common Shares is an
attractive investment opportunity and an appropriate use of funds.
At MDS Inc., our more than 10,000 highly skilled people provide
enabling products and services for the development of drugs and the
diagnosis and management of disease. We focus on helping to
discover new drugs, assisting doctors to diagnose and treat
patients and preventing the spread of disease. Find out more about
MDS Inc. at http://www.mdsintl.com/ or by calling 1-888-MDS-7222,
24 hours a day. This document contains forward-looking statements.
Some forward looking statements may be identified by words like
"expects", "anticipates", "plans", "intends", "indicates" or
similar expressions. The statements are not a guarantee of future
performance and are inherently subject to risks and uncertainties.
The Company's actual results could differ materially from those
currently anticipated due to a number of factors, including, but
not limited to, successful integration of structural changes,
including restructuring plans, acquisitions, technical or
manufacturing or distribution issues, the competitive environment
for the Company's products, the degree of market penetration of the
Company's products, and other factors set forth in reports and
other documents filed by the Company with Canadian and US
securities regulatory authorities from time to time. DATASOURCE:
MDS Inc. CONTACT: Sharon Mathers, Vice-President, Investor
Relations, (416) 675-6777 ext. 2695,
Copyright